Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 10, 2009, Pages 1578-1586

  Sovershaev, Mikhail A ^a,b,d   Egorina, Elena M ^b,d   Hansen, John Bjarne ^a,c   Østerud, Bjarne ^b   Pacher, Pál ^e   Stasch, Johannes Peter ^f   Evgenov, Oleg V ^d  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b Institute of Medical Biology   (China)

^c UNIVERSITY OF TROMSØ   (Norway)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^f BAYER PHARMA AG   (Germany)

Author keywords

BAY 41 2272; BAY 58 2667; Procoagulant activity; Soluble guanylate cyclase; Tissue factor

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; GUANYLATE CYCLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PROCOAGULANT; SMALL INTERFERING RNA; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA; 3 (4 AMINO 5 CYCLOPROPYLPYRIMIDINE 2 YL) 1 (2 FLUOROBENZYL) 1H PYRAZOLO(3,4 B)PYRIDINE; 3-(4-AMINO-5-CYCLOPROPYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO(3,4-B)PYRIDINE; BENZOIC ACID DERIVATIVE; CELL RECEPTOR; CYCLIC GMP; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SOLUBLE GUANYLYL CYCLASE;

ADULT; AGONIST; ALPHA CHAIN; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INHIBITION KINETICS; MALE; MONOCYTE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION INHIBITION; TRANSCRIPTION INITIATION; UMBILICAL VEIN; WESTERN BLOTTING; CELL SURVIVAL; DRUG ANTAGONISM; DRUG POTENTIATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; BENZOIC ACIDS; CELL SURVIVAL; CYCLIC GMP; ENDOTHELIAL CELLS; FEMALE; GUANYLATE CYCLASE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; NF-KAPPA B; PYRAZOLES; PYRIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THROMBOPLASTIN;

EID: 70349569055     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.192690     Document Type: Article

References (38)

1. Mackman N. Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 2006;36:104-107.
2. Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol. 2007;14:55-61.
3. Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol. 1996;3:379-384.
4. Stemerman MB, Pitlick FA, Dembitzer HM. Electron microscopic immu-nohistochemical identification of endothelial cells in the rabbit. Circ Res. 1976;38:146-156.
5. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest. 1983;71:1893-1896.
6. Egorina EM, Sovershaev MA, Olsen JO, Osterud B. Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer. Blood. 2008;111:1208-1216.
7. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113:722-731.
8. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, Cool CD, Taubman MB. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293:L583-L590.
9. Riewald M, Ruf W. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med. 2002;12:149-154.
10. Lyberg T. Effect of cyclic AMP and cyclic GMP on thromboplastin (factor III) synthesis in human monocytes in vitro. Thromb Haemost. 1983;50:804-809.
11. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755-768.
12. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation. 2004;110:2253-2259.
13. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006;113:286-295.
14. Evgenov OV, Kohane DS, Bloch KD, Stasch JP, Volpato GP, Bellas E, Evgenov NV, Buys ES, Gnoth MJ, Graveline AR, Liu R, Hess DR, Langer R, Zapol WM. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med. 2007;176:1138-1145.
15. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC Jr. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation. 2003;107:686-689.
16. Hobbs AJ, Moncada S. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. Vascul Pharmacol. 2003;40:149-154.
17. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bolkow D, Weissmann N, Muck W, Unger S, Wensing G, Schermuly RT, Ghofrani HA. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33:785-792.
18. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, Frey R. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009;119:2781-2788.
19. Egorina EM, Sovershaev MA, Osterud B. In-cell Western assay: a new approach to visualize tissue factor in human monocytes. J Thromb Haemost. 2006;4:614-620.
20. Osterud B. Platelet activating factor enhancement of lipopolysaccharide- induced tissue factor activity in monocytes: requirement of platelets and granulocytes. J Leukoc Biol. 1992;51:462-465.
21. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1:1458-1461.
22. Egorina EM, Sovershaev MA, Bjorkoy G, Gruber FX, Olsen JO, Parhami-Seren B, Mann KG, Osterud B. Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability. Arterioscler Thromb Vasc Biol. 2005;25:1493-1498.
23. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol. 2006; 26:456-461.
24. Connelly L, Jacobs AT, Palacios-Callender M, Moncada S, Hobbs AJ. Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem. 2003;278: 26480-26487.
25. Mackman N, Brand K, Edgington TS. Lipopolysaccharide-mediated tran-scriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. J Exp Med. 1991;174:1517-1526.
26. Martin E, Baeuerle PA, Waldher R, Kisiel W, Ziegler R, Stern DM, Nawroth PP. Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem. 1995;270: 26419-26432.
27. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem. 1989;264:20705-20713.
28. Brand K, Fowler BJ, Edgington TS, Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttran-scriptional levels in response to lipopolysaccharide. Mol Cell Biol. 1991; 11:4732-4738.
29. Pan SL, Guh JH, Peng CY, Chang YL, Cheng FC, Chang JH, Kuo SC, Lee FY, Teng CM. A potential role of YC-1 on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models. Thromb Haemost. 2005;93:940-948.
30. Lu DY, Tang CH, Liou HC, Teng CM, Jeng KC, Kuo SC, Lee FY, Fu WM. YC-1 attenuates LPS-induced proinflammatory responses and activation of nuclear factor-kappaB in microglia. Br J Pharmacol. 2007;151:396-405.
31. Pinder PB, Hunt JA, Zacharski LR. In vitro stimulation of monocyte tissue factor activity by autologous platelets. Am J Hematol. 1985;19:317-325.
32. Osterud B, Rapaport SI, Lavine KK. Factor V activity of platelets: evidence for an activated factor V molecule and for a platelet activator. Blood. 1977;49:819-834.
33. Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, Sticherling C, Meinl C, May A, Schomig A. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997;95:2387-2394. (Pubitemid 27224733)
34. Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97:1525-1534.
35. Neumann FJ, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol. 1999;34:1420-1426.
36. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
37. Lindmark E, Tenno T, Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol. 2000;20:2322-2328.
38. Ahluwalia A, Foster P, Scotland RS, McLean PG, Mathur A, Perretti M, Moncada S, Hobbs AJ. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A. 2004;101:1386-1391.